MCID: PST020
MIFTS: 43

Postpoliomyelitis Syndrome

Categories: Infectious diseases, Muscle diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Postpoliomyelitis Syndrome

MalaCards integrated aliases for Postpoliomyelitis Syndrome:

Name: Postpoliomyelitis Syndrome 12 20 58 44 15 17 71
Postpolio Syndrome 12 20 58 32
Post-Polio Syndrome 74 53
Post-Polio Muscular Atrophy 20
Post-Poliomyelitic Syndrome 20
Postpoliomyelitic Syndrome 58
Postpoliomyelitis Sequelae 58
Post Polio Syndrome 20
Post-Polio Sequelae 20
Polio Late Effects 20
Postpolio Sequelae 58

Characteristics:

Orphanet epidemiological data:

58
postpoliomyelitis syndrome
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4952
MeSH 44 D016262
SNOMED-CT 67 31097004
ICD10 32 G14
ICD10 via Orphanet 33 G14
UMLS via Orphanet 72 C0080040
Orphanet 58 ORPHA2942
UMLS 71 C0080040

Summaries for Postpoliomyelitis Syndrome

NINDS : 53 Post-polio syndrome (PPS) is a condition that affects polio survivors many years after recovery from an initial attack of the poliomyelitis virus. PPS is characterized by a further weakening of muscles that were previously affected by the polio infection. The most common symptoms include slowly progressive muscle weakness, fatigue (both general and muscular), and a decrease in muscle size (muscular atrophy). Pain from joint deterioration and increasing skeletal deformities such as scoliosis are common. Some individuals experience only minor symptoms, while others develop more visible muscle weakness and atrophy.  PPS is rarely life-threatening but the symptoms can interfere significantly with the individual's capacity to function independently.   While polio is contagious, PPS is not transmissible.  Only a polio survivor can develop PPS.

MalaCards based summary : Postpoliomyelitis Syndrome, also known as postpolio syndrome, is related to poliomyelitis and guillain-barre syndrome. An important gene associated with Postpoliomyelitis Syndrome is LCOR (Ligand Dependent Nuclear Receptor Corepressor), and among its related pathways/superpathways are MSP-RON Signaling and Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs). The drugs Modafinil and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include spinal cord and skeletal muscle, and related phenotypes are muscle weakness and fatigue

Disease Ontology : 12 A poliomyelitis that results in atrophy located in muscle, many years after the initial infection, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3. It is characterized by new weakening in muscles that were previously affected by the polio infection and in muscles that were unaffected. The infection has symptom muscle weakness, has symptom muscle pain, has symptom sleep apnea, and has symptom breathing problems.

GARD : 20 Post polio syndrome (PPS) is a condition that affects polio survivors years after recovery from the initial polio illness. Symptoms and severity vary among affected people and may include muscle weakness and a gradual decrease in the size of muscles (atrophy); muscle and joint pain; fatigue; difficulty with gait; respiratory problems; and/or swallowing problems. Only a polio survivor can develop PPS. While polio is a contagious disease, PPS is not. The exact cause of PPS years after the first episode of polio is unclear, although several theories have been proposed. Treatment focuses on reducing symptoms and improving quality of life.

Wikipedia : 74 Post-polio syndrome (PPS, poliomyelitis sequelae) is a group of latent symptoms of poliomyelitis... more...

Related Diseases for Postpoliomyelitis Syndrome

Diseases related to Postpoliomyelitis Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 poliomyelitis 30.4 TNF PVR C17orf80
2 guillain-barre syndrome 29.4 TNF HCRT
3 sleep apnea 29.3 TNF IGF1 HCRT
4 sleep disorder 29.2 TNF IGF1 HCRT
5 motor neuron disease 11.2
6 dysphagia 10.2
7 spinal cord injury 10.2
8 restless legs syndrome 10.1
9 myotonic dystrophy 10.1
10 high-grade astrocytoma 10.1 KLK9 KLK6
11 inclusion body myositis 10.1
12 myositis 10.1
13 scoliosis 10.1
14 spondylosis 10.1
15 myelitis 10.1
16 paresthesia 10.1
17 pain agnosia 10.0
18 hypothyroidism 10.0
19 myopathy 10.0
20 chronic fatigue syndrome 10.0
21 chronic pain 10.0
22 myoclonus 10.0
23 myotonic disease 10.0
24 hereditary neuropathies 10.0
25 multiple sclerosis 9.9
26 esophageal cancer 9.9
27 spondylosis, cervical 9.9
28 insulin-like growth factor i 9.9
29 body mass index quantitative trait locus 1 9.9
30 coronary heart disease 1 9.9
31 angina pectoris 9.9
32 secondary progressive multiple sclerosis 9.9
33 basal ganglia calcification 9.9
34 mumps 9.9
35 pyelonephritis 9.9
36 mononeuropathy 9.9
37 iron metabolism disease 9.9
38 lipid metabolism disorder 9.9
39 progressive muscular atrophy 9.9
40 neuromuscular junction disease 9.9
41 somatoform disorder 9.9
42 herpes simplex 9.9
43 measles 9.9
44 chickenpox 9.9
45 bulbar polio 9.9
46 cytokine deficiency 9.9
47 wallerian degeneration 9.9
48 atrial fibrillation and stroke 9.9
49 muscular dystrophy, duchenne type 9.9
50 paralytic poliomyelitis 9.9

Graphical network of the top 20 diseases related to Postpoliomyelitis Syndrome:



Diseases related to Postpoliomyelitis Syndrome

Symptoms & Phenotypes for Postpoliomyelitis Syndrome

Human phenotypes related to Postpoliomyelitis Syndrome:

58 31 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
3 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
4 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
5 hypersomnia 58 31 frequent (33%) Frequent (79-30%) HP:0100786
6 difficulty climbing stairs 58 31 frequent (33%) Frequent (79-30%) HP:0003551
7 dysarthria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001260
8 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
9 respiratory insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0002093
10 skeletal muscle atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003202
11 fasciculations 58 31 occasional (7.5%) Occasional (29-5%) HP:0002380
12 muscle spasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0003394
13 abnormal joint morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001367
14 hypoventilation 58 31 very rare (1%) Very rare (<4-1%) HP:0002791
15 sleep disturbance 58 Occasional (29-5%)
16 abnormality of higher mental function 58 Frequent (79-30%)
17 pain 58 Very frequent (99-80%)

Drugs & Therapeutics for Postpoliomyelitis Syndrome

Drugs for Postpoliomyelitis Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
2 Pharmaceutical Solutions Phase 2, Phase 3
3 Immunologic Factors Phase 2, Phase 3
4 Immunoglobulins Phase 2, Phase 3
5 gamma-Globulins Phase 2, Phase 3
6 Antibodies Phase 2, Phase 3
7 Immunoglobulins, Intravenous Phase 2, Phase 3
8 Rho(D) Immune Globulin Phase 2, Phase 3
9 Central Nervous System Stimulants Phase 3
10 Vaccines Phase 2
11 Antioxidants

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 "Treatment With L-citrulline in Patients With Post-polio Syndrome - a Randomized Double Blind Placebo Controlled Study" Completed NCT02801071 Phase 3 15g L-citrulline daily p.o.;Placebo
2 Post-Polio Syndrome Treated With Intravenous Immunoglobulin (IvIg) Completed NCT00231439 Phase 2, Phase 3 IvIg
3 Intravenous Immunoglobulins for Post-Polio Syndrome Completed NCT01537575 Phase 3
4 A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome Recruiting NCT02176863 Phase 2, Phase 3
5 Modafinil in the Treatment of Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
6 A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Therapeutic Effect of the Association of L-carnitine and Piracetam as an Adjuvant Therapy in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome Withdrawn NCT01549847 Phase 3 L-carnitine and piracetam;Placebo
7 A Randomized, Blinded and Controlled Phase II Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell) in Infants. Completed NCT03902054 Phase 2
8 Study of Mental Fatigue in Polio Survivors Unknown status NCT00487487
9 The Effect of Adding Whole-Body Vibration Exercises to Home Exercise Program on Muscle Strength in Patients With Postpolio Syndrome Completed NCT04387864
10 Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS): A Randomized, Two-Arm, Parallel, Double-Blind, Multi-Centre, Placebo Controlled Study Completed NCT00160082 Xepol
11 Oral Glutathione and Health Outcomes Among Persons With Post-Polio Syndrome Completed NCT01402570
12 Comparison of Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics Between Post-Polio Patients and Healthy Controls: A Pilot Study Completed NCT03064711
13 The Impact of an Arm Ergometry Training Programme on Cardiovascular Fitness, Energy Cost of Walking and Fatigue in Prior Polio Patients Completed NCT01271530
14 Project Enhance for Adults Aging With Long-Term Physical Disability Completed NCT02815878
15 Diagnosis of Neuromuscular Disorders With Specialized Electromyographic Studies Completed NCT00004553
16 Post-Polio Motor Neuron Disease: Clinical, Virological, and Immunological Studies Completed NCT00001185
17 Evaluating the Effectiveness of a Serious Game to Enhance Self-Management Skills Among Adolescents and Young Adults With Spinal Cord Dysfunction Completed NCT02341950
18 Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin: a Retrospective Study of Efficacy on Clinical and Isokinetic Criteria Completed NCT04004390
19 Efficacy and Mechanism of a Community Wellness Promotion Program for Middle-aged Adults Living With Long-term Physical Disability Recruiting NCT03653390
20 Characterization of the Immunological Profile Patients With Post-polio Syndrome in Comparison With These Control Subjects Recruiting NCT03396783
21 Quantitative Spinal Cord Gray Matter Imaging in Post Polio Syndrome Active, not recruiting NCT03561623
22 Micro-processor Controlled Knee-Ankle-Foot Orthosis (C-Brace) Versus Stance-control Knee-Ankle-Foot Orthosis (SCO): Functional Outcomes in Individuals With Lower Extremity Impairment Active, not recruiting NCT02089880

Search NIH Clinical Center for Postpoliomyelitis Syndrome

Cochrane evidence based reviews: postpoliomyelitis syndrome

Genetic Tests for Postpoliomyelitis Syndrome

Anatomical Context for Postpoliomyelitis Syndrome

MalaCards organs/tissues related to Postpoliomyelitis Syndrome:

40
Spinal Cord, Skeletal Muscle

Publications for Postpoliomyelitis Syndrome

Articles related to Postpoliomyelitis Syndrome:

(show top 50) (show all 260)
# Title Authors PMID Year
1
Postpoliomyelitis Syndrome and Reversal With Sugammadex: A Case Report. 61
32990207 2020
2
Longitudinal associations between physical activity, anxiety, and depression in adults with long-term physical disabilities. 61
32202825 2020
3
Corticomotor Excitability in Two Kinds of Motor Neuron Diseases: A Study on the Patients With Amyotrophic Lateral Sclerosis and Poliomyelitis Survivors. 61
32501947 2020
4
A twelve-week, four-arm, randomized, double-blind, placebo-controlled, phase 2 prospective clinical trial to evaluate the efficacy and safety of an anthroposophic multimodal treatment on chronic pain in outpatients with postpolio syndrome. 61
32162497 2020
5
A very long-term longitudinal follow-up of persons with late effects of polio. 61
32043852 2020
6
Kaposi sarcoma in a patient with postpolio syndrome. 61
31886796 2019
7
Experiences of Speaking With Noninvasive Positive Pressure Ventilation: A Qualitative Investigation. 61
31306604 2019
8
Postpolio Syndrome: A Review of Lived Experiences of Patients. 61
31392174 2019
9
Sex/gender disparities in health outcomes of individuals with long-term disabling conditions. 61
30299140 2019
10
Secondary health conditions and social role satisfaction in adults with long-term physical disability. 61
31045428 2019
11
Postpolio syndrome and the late effects of poliomyelitis. Part 1. pathogenesis, biomechanical considerations, diagnosis, and investigations. 61
29752819 2018
12
Anxiety, depression, and function in individuals with chronic physical conditions: A longitudinal analysis. 61
30299138 2018
13
Ultrasound-Guided Carpal Tunnel Release Using Dynamic Expansion of the Transverse Safe Zone in a Patient With Postpolio Syndrome: A Case Report. 61
29518587 2018
14
Neurological Symptoms in Danes with a History of Poliomyelitis: Lifelong Follow-Up of Late Symptoms, their Association with Initial Symptoms of Polio, and Presence of Postpolio Syndrome. 61
30836354 2018
15
Restless legs syndrome is highly prevalent in patients with postpolio syndrome. 61
29183652 2018
16
Systematic review of the evidence on orthotic devices for the management of knee instability related to neuromuscular and central nervous system disorders. 61
28877943 2017
17
Resilience and Function in Adults With Physical Disabilities: An Observational Study. 61
27993585 2017
18
Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. 61
28436583 2017
19
Growing Older With a Physical Disability: A Special Application of the Successful Aging Paradigm. 61
27702838 2017
20
A patient with postpolio syndrome developed cauda equina syndrome after neuraxial anesthesia: A case report. 61
28235527 2017
21
Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. 61
28087891 2017
22
Health related quality of life in Turkish polio survivors: impact of post-polio on the health related quality of life in terms of functional status, severity of pain, fatigue, and social, and emotional functioning. 61
28137397 2017
23
No Reduction of Severe Fatigue in Patients With Postpolio Syndrome by Exercise Therapy or Cognitive Behavioral Therapy: Results of an RCT. 61
26253175 2016
24
Pyridostigmine: Postpoliomyelitis Syndrome. 61
27303089 2016
25
Effects of a Tailored Positive Psychology Intervention on Well-Being and Pain in Individuals With Chronic Pain and a Physical Disability: A Feasibility Trial. 61
25724020 2016
26
Response to the Letter to the Editor on "Review of Secondary Health Conditions in Postpolio Syndrome". 61
26057026 2015
27
Does a subgroup of postpolio patients need different management? 61
25899845 2015
28
Resilience predicts functional outcomes in people aging with disability: a longitudinal investigation. 61
25757790 2015
29
Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome. 61
25845857 2015
30
Treatment for postpolio syndrome. 61
25984923 2015
31
Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis. 61
25886512 2015
32
Falls among adults aging with disability. 61
25449191 2015
33
Review of secondary health conditions in postpolio syndrome: prevalence and effects of aging. 61
25122095 2015
34
[Health related quality of life in Turkish polio survivors: impact of post-polio on the health related quality of life in terms of functional status, severity of pain, fatigue, and social, and emotional functioning]. 61
25772658 2015
35
Alterations in muscle proteome of patients diagnosed with amyotrophic lateral sclerosis. 61
24846852 2014
36
Complications and outcomes of complex spine reconstructions in poliomyelitis-associated spinal deformities: a single-institution experience. 61
24825153 2014
37
Circadian variation of fatigue in paralytic poliomyelitis and postpolio syndrome: just fatigue or masked restless legs syndrome? 61
24964120 2014
38
Determining the anaerobic threshold in postpolio syndrome: comparison with current guidelines for training intensity prescription. 61
24491465 2014
39
Prevalence and impact of pain in adults aging with a physical disability: comparison to a US general population sample. 61
23887334 2014
40
Brain volume and fatigue in patients with postpoliomyelitis syndrome. 61
24060387 2014
41
Vaccine-derived poliomyelitis and postpolio syndrome: an Italian Cutter Incident. 61
25057364 2014
42
Few patients with neurodegenerative disorders require spinal surgery. 61
24843817 2014
43
Normal serum levels of immune complexes in postpolio patients. 61
25009767 2014
44
Statin-induced myopathy in a patient with previous poliomyelitis. 61
23370588 2013
45
[Polio paralytic. New problems: postpolio syndrome]. 61
24322288 2013
46
Health-related quality of life and supportive care in patients with rare long-term neurological conditions. 61
23001492 2013
47
A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. 61
23683859 2013
48
Living with polio and postpolio syndrome in the United Kingdom. 61
22816389 2013
49
Test-retest reliability of the 6-min walk test in patients with postpolio syndrome. 61
23640326 2013
50
Self-reported depression and physical activity in adults with mobility impairments. 61
23164977 2013

Variations for Postpoliomyelitis Syndrome

Expression for Postpoliomyelitis Syndrome

Search GEO for disease gene expression data for Postpoliomyelitis Syndrome.

Pathways for Postpoliomyelitis Syndrome

Pathways related to Postpoliomyelitis Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.61 TNF KLK9 KLK6 KLK1
2 10.28 KLK1 IGF1

GO Terms for Postpoliomyelitis Syndrome

Cellular components related to Postpoliomyelitis Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 TNF PVR PAM KLK9 KLK6 IGF1
2 secretory granule GO:0030141 9.02 PAM KLK9 KLK6 KLK1 HCRT

Biological processes related to Postpoliomyelitis Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase B signaling GO:0043491 9.16 TNF IGF1
2 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 8.96 TNF IGF1
3 regulation of protein secretion GO:0050708 8.62 TNF PAM

Molecular functions related to Postpoliomyelitis Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.46 MINDY1 KLK9 KLK6 KLK1
2 serine-type endopeptidase activity GO:0004252 9.13 KLK9 KLK6 KLK1
3 serine-type peptidase activity GO:0008236 8.8 KLK9 KLK6 KLK1

Sources for Postpoliomyelitis Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....